Clofarabine

CHEMBL1750 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
303.7 g/mol
LogP
0.9
Phase
4

A second-generation purine nucleoside analogue that interferes with DNA synthesis and repair, used to treat relapsed or refractory acute lymphoblastic leukemia in children. It inhibits both ribonucleotide reductase and DNA polymerase, triggering cancer cell death.

分子量

303.6800 g/mol

LogP

0.90

TPSA

119.00 Ų

リピンスキーの五則

適合

治療領域

作用機序

Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F

InChI

InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1

Molecular Formula

C10H11ClFN5O3

HBD / HBA

3 / 8

回転可能結合数

2

重原子数

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A second-generation purine nucleoside analogue that interferes with DNA synthesis and repair, used to treat relapsed or refractory acute lymphoblastic leukemia in children. It inhibits both ribonucleotide reductase and DNA polymerase, triggering cancer cell death.

Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.

Yes, Clofarabine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1750. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 119182. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.